首页 > 最新文献

Cancer cell & microenvironment最新文献

英文 中文
The regulation of snail: on the ubiquitin edge 蜗牛的调控:在泛素边缘上
Pub Date : 2017-07-03 DOI: 10.14800/CCM.1567
Qian Yu, Binhua P. Zhou, Yadi Wu
Metastasis accounts for a majority of cancer death. One key feature during metastasis is epithelial-mesenchymal transition (EMT), which is regulated by transcription factors such as Snail and Twist. In non-malignant cells, Snail has a short half-life and is degraded via ubiquitination, but its stability is increased in cancer cell. However, the mechanism by which Snail escapes ubiquitination and degradation remains unknown. Recently, we found that Dub3 is a deubiquinase of Snail. Most importantly, we determined that Dub3 responded to extracellular signals such as IL-6, and that the resultant signaling prevented Snail degradation, and promoted cancer growth, invasion, and migration. In this highlight, we present a concise picture of how the transcription factor Snail is regulated by ubiquitination in cancer cells, the role of Dub3 in this process, and its potential use as a treatment target.
转移是癌症死亡的主要原因。转移过程中的一个关键特征是上皮-间质转化(EMT),这是由转录因子如Snail和Twist调节的。在非恶性细胞中,蜗牛的半衰期短,可通过泛素化降解,但在癌细胞中其稳定性增加。然而,蜗牛逃脱泛素化和降解的机制尚不清楚。最近,我们发现Dub3是蜗牛的一种去泛素酶。最重要的是,我们确定Dub3对细胞外信号如IL-6有反应,由此产生的信号阻止了Snail降解,并促进了癌症的生长、侵袭和迁移。在这篇重点文章中,我们简要介绍了癌细胞中转录因子Snail是如何被泛素化调节的,Dub3在这一过程中的作用,以及它作为治疗靶点的潜在用途。
{"title":"The regulation of snail: on the ubiquitin edge","authors":"Qian Yu, Binhua P. Zhou, Yadi Wu","doi":"10.14800/CCM.1567","DOIUrl":"https://doi.org/10.14800/CCM.1567","url":null,"abstract":"Metastasis accounts for a majority of cancer death. One key feature during metastasis is epithelial-mesenchymal transition (EMT), which is regulated by transcription factors such as Snail and Twist. In non-malignant cells, Snail has a short half-life and is degraded via ubiquitination, but its stability is increased in cancer cell. However, the mechanism by which Snail escapes ubiquitination and degradation remains unknown. Recently, we found that Dub3 is a deubiquinase of Snail. Most importantly, we determined that Dub3 responded to extracellular signals such as IL-6, and that the resultant signaling prevented Snail degradation, and promoted cancer growth, invasion, and migration. In this highlight, we present a concise picture of how the transcription factor Snail is regulated by ubiquitination in cancer cells, the role of Dub3 in this process, and its potential use as a treatment target.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87211324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Emerging role of SHARPIN in hepatocellular carcinoma progression SHARPIN在肝细胞癌进展中的新作用
Pub Date : 2017-05-24 DOI: 10.14800/CCM.1540
Yasuo Tanaka, R. Tateishi, K. Koike
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the leading cause of cancer-related death, especially in less economically developed regions. Despite recent progress in the diagnosis and therapy of HCC, the long-term survival rate of HCC patients is unacceptably low, in part due to the frequent development of vascular invasion or distant metastasis. The cellular functions of shank-associated RH domain-interacting protein (SHARPIN, also known as SIPL1) include the regulation of inflammation, apoptosis, immune signaling, and cell motility. SHARPIN is up-regulated in various types of cancers including HCC and has been implicated in the genesis and progression of malignant tumors, but its exact role in tumorigenesis is largely unknown. Here we present evidence supporting a role for SHARPIN in HCC invasion and progression. We also discuss the potential of SHARPIN and related genes as therapeutic targets for this currently incurable cancer.
肝细胞癌(HCC)是世界上最常见的癌症之一,也是癌症相关死亡的主要原因,特别是在经济欠发达地区。尽管近年来HCC的诊断和治疗取得了进展,但HCC患者的长期生存率低得令人无法接受,部分原因是其经常发生血管侵犯或远处转移。小腿相关RH结构域相互作用蛋白(SHARPIN,也称为SIPL1)的细胞功能包括调节炎症、凋亡、免疫信号传导和细胞运动。SHARPIN在包括HCC在内的各种类型的癌症中上调,并与恶性肿瘤的发生和发展有关,但其在肿瘤发生中的确切作用在很大程度上尚不清楚。在这里,我们提出证据支持SHARPIN在HCC侵袭和进展中的作用。我们还讨论了SHARPIN和相关基因作为这种目前无法治愈的癌症的治疗靶点的潜力。
{"title":"Emerging role of SHARPIN in hepatocellular carcinoma progression","authors":"Yasuo Tanaka, R. Tateishi, K. Koike","doi":"10.14800/CCM.1540","DOIUrl":"https://doi.org/10.14800/CCM.1540","url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the leading cause of cancer-related death, especially in less economically developed regions. Despite recent progress in the diagnosis and therapy of HCC, the long-term survival rate of HCC patients is unacceptably low, in part due to the frequent development of vascular invasion or distant metastasis. The cellular functions of shank-associated RH domain-interacting protein (SHARPIN, also known as SIPL1) include the regulation of inflammation, apoptosis, immune signaling, and cell motility. SHARPIN is up-regulated in various types of cancers including HCC and has been implicated in the genesis and progression of malignant tumors, but its exact role in tumorigenesis is largely unknown. Here we present evidence supporting a role for SHARPIN in HCC invasion and progression. We also discuss the potential of SHARPIN and related genes as therapeutic targets for this currently incurable cancer.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73716852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Inhibition of nucleo-cytoplasmic shuttling through XPO1/CRM1: a unique therapeutic approach for treatment of haematological and solid malignancies 通过XPO1/CRM1抑制核细胞质穿梭:治疗血液病和实体恶性肿瘤的独特治疗方法
Pub Date : 2017-03-13 DOI: 10.14800/CCM.1516
S. Sneha, P. NagareR., Bindhya Sadhanandhan, Ram Shankar, S. Suresh, T. Ganesan, M. Garg
Cancer is one of the leading cause of morbidity and mortality worldwide. Regulated nucleo-cytoplasmic shuttling is very crucial for maintaining cellular homeostasis. Emerging evidence suggests that deregulation of the nucleo-cytoplasmic transport results in abnormal cell growth, cell cycle, apoptosis, tumor progression and drug resistance. Exportin-1 (also called as chromosome region maintenance 1) belongs to karyopherin-β superfamily and is the main mediator of nuclear export in several cell types. The XPO1 / CRM1 protein is overexpressed in liposarcoma, Ewing sarcoma, ovarian carcinoma, pancreatic cancer, hepatocellular carcinoma, lung carcinoma, osteosarcoma, gastric carcinoma, melanoma, glioma, acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid/lymphoid leukemia as well as multiple myeloma. Hot spot mutations were observed in many cancers. Higher levels of XPO1 / CRM1 are associated with poor prognosis, resistance to chemotherapy and recurrence in a large number of human malignancies. There are growing evidence that provided the foundation that inhibition of nuclear export by inhibiting nuclear export receptor ( XPO1 ) might be a potential targeted therapeutic approach for the treatment of human cancers in the clinic. In the present review, we will discuss the role of XPO1 in cancers and potential of selective inhibitors of nuclear export ( XPO1 inhibitors) to restore the normal function of tumor suppressor and growth regulatory proteins by blocking their export. Selinexor (KPT-330) is an orally available, highly potent and is being tested in human phase-I/II clinical trials in both haematological and solid malignancies.
癌症是全世界发病率和死亡率的主要原因之一。核细胞质穿梭调节对维持细胞内稳态至关重要。越来越多的证据表明,核质转运的失调导致细胞生长异常、细胞周期、细胞凋亡、肿瘤进展和耐药。输出蛋白-1(也称为染色体区域维持1)属于核丝蛋白-β超家族,是几种细胞类型的核输出的主要介质。XPO1 / CRM1蛋白在脂肪肉瘤、尤因肉瘤、卵巢癌、胰腺癌、肝细胞癌、肺癌、骨肉瘤、胃癌、黑色素瘤、胶质瘤、急性髓性白血病、急性淋巴细胞白血病、慢性髓性/淋巴性白血病以及多发性骨髓瘤中过表达。在许多癌症中都观察到热点突变。在大量人类恶性肿瘤中,较高水平的XPO1 / CRM1与预后不良、化疗耐药和复发有关。越来越多的证据表明,通过抑制核输出受体(XPO1)抑制核输出可能成为临床治疗人类癌症的潜在靶向治疗方法。在这篇综述中,我们将讨论XPO1在癌症中的作用,以及选择性核输出抑制剂(XPO1抑制剂)通过阻断肿瘤抑制蛋白和生长调节蛋白的输出来恢复其正常功能的潜力。Selinexor (KPT-330)是一种口服有效的高效药物,目前正在血液和实体恶性肿瘤的人体i /II期临床试验中进行测试。
{"title":"Inhibition of nucleo-cytoplasmic shuttling through XPO1/CRM1: a unique therapeutic approach for treatment of haematological and solid malignancies","authors":"S. Sneha, P. NagareR., Bindhya Sadhanandhan, Ram Shankar, S. Suresh, T. Ganesan, M. Garg","doi":"10.14800/CCM.1516","DOIUrl":"https://doi.org/10.14800/CCM.1516","url":null,"abstract":"Cancer is one of the leading cause of morbidity and mortality worldwide. Regulated nucleo-cytoplasmic shuttling is very crucial for maintaining cellular homeostasis. Emerging evidence suggests that deregulation of the nucleo-cytoplasmic transport results in abnormal cell growth, cell cycle, apoptosis, tumor progression and drug resistance. Exportin-1 (also called as chromosome region maintenance 1) belongs to karyopherin-β superfamily and is the main mediator of nuclear export in several cell types. The XPO1 / CRM1 protein is overexpressed in liposarcoma, Ewing sarcoma, ovarian carcinoma, pancreatic cancer, hepatocellular carcinoma, lung carcinoma, osteosarcoma, gastric carcinoma, melanoma, glioma, acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid/lymphoid leukemia as well as multiple myeloma. Hot spot mutations were observed in many cancers. Higher levels of XPO1 / CRM1 are associated with poor prognosis, resistance to chemotherapy and recurrence in a large number of human malignancies. There are growing evidence that provided the foundation that inhibition of nuclear export by inhibiting nuclear export receptor ( XPO1 ) might be a potential targeted therapeutic approach for the treatment of human cancers in the clinic. In the present review, we will discuss the role of XPO1 in cancers and potential of selective inhibitors of nuclear export ( XPO1 inhibitors) to restore the normal function of tumor suppressor and growth regulatory proteins by blocking their export. Selinexor (KPT-330) is an orally available, highly potent and is being tested in human phase-I/II clinical trials in both haematological and solid malignancies.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82105586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A double-edged sword - the role of human ADAM17 in NK cell activity 一把双刃剑——人类ADAM17在NK细胞活性中的作用
Pub Date : 2017-02-06 DOI: 10.14800/CCM.1495
Dominik Schmiedel, O. Mandelboim, Pinchas Tsukerman
ADAM17 is a pleiotropic sheddase that regulates the activity of diverse membrane-anchored proteins by proteolytic cleavage. Also, many immune functions depend on ADAM17 activity, for instance CD16 and TNFα, two key effector molecules of Natural Killer cells, are cleaved by this enzyme. Whereas CD16 is shed from the surface and therefore its activity is terminated by ADAM17, TNFα requires shedding to be soluble and fulfil its effector functions. Due to these antagonistic effects on immune system activity, clinical benefits of ADAM17 inhibition for the treatment of cancer patients are hard to predict. Recently, we reported of a patient with a very rare genetic deficiency of ADAM17 leading to a complete loss of ADAM17 protein. We characterized the patient’s PBMCs for cytokine secretion in response to LPS stimulation, as well as for antibody-dependent cellular cytotoxicity (ADCC) effector functions and IFNγ release following engagement of CD16. In this short review, we highlight these recent findings and discuss putative consequences for the clinical use of inhibitors for ADAM17.
ADAM17是一种多效性脱落酶,通过蛋白水解裂解调节多种膜锚定蛋白的活性。此外,许多免疫功能依赖于ADAM17的活性,例如CD16和TNFα,自然杀伤细胞的两个关键效应分子,被这种酶切割。虽然CD16从表面脱落,因此其活性被ADAM17终止,但TNFα需要脱落才能溶解并发挥其效应功能。由于这些对免疫系统活性的拮抗作用,抑制ADAM17治疗癌症患者的临床效益难以预测。最近,我们报道了一个非常罕见的ADAM17基因缺陷导致ADAM17蛋白完全缺失的患者。我们对患者的PBMCs在LPS刺激下的细胞因子分泌、抗体依赖性细胞毒性(ADCC)效应功能和CD16作用后的IFNγ释放进行了表征。在这篇简短的综述中,我们强调了这些最近的发现,并讨论了临床使用ADAM17抑制剂的可能后果。
{"title":"A double-edged sword - the role of human ADAM17 in NK cell activity","authors":"Dominik Schmiedel, O. Mandelboim, Pinchas Tsukerman","doi":"10.14800/CCM.1495","DOIUrl":"https://doi.org/10.14800/CCM.1495","url":null,"abstract":"ADAM17 is a pleiotropic sheddase that regulates the activity of diverse membrane-anchored proteins by proteolytic cleavage. Also, many immune functions depend on ADAM17 activity, for instance CD16 and TNFα, two key effector molecules of Natural Killer cells, are cleaved by this enzyme. Whereas CD16 is shed from the surface and therefore its activity is terminated by ADAM17, TNFα requires shedding to be soluble and fulfil its effector functions. Due to these antagonistic effects on immune system activity, clinical benefits of ADAM17 inhibition for the treatment of cancer patients are hard to predict. Recently, we reported of a patient with a very rare genetic deficiency of ADAM17 leading to a complete loss of ADAM17 protein. We characterized the patient’s PBMCs for cytokine secretion in response to LPS stimulation, as well as for antibody-dependent cellular cytotoxicity (ADCC) effector functions and IFNγ release following engagement of CD16. In this short review, we highlight these recent findings and discuss putative consequences for the clinical use of inhibitors for ADAM17.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90089354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor treating field therapy in non-MGMT-Methylated newly diagnosed glioblastoma: is there a role for temozolomide? 非mtmt甲基化新诊断胶质母细胞瘤的肿瘤治疗野疗法:替莫唑胺是否有作用?
Pub Date : 2017-01-30 DOI: 10.14800/CCM.1502
H. Robins, J. Kuo, D. Deming
A Research Highlight of a recently published paper: “The effects of tumor treating fields (and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells” (J Clin Neurosci 2017; 36:120-124) is presented. Introductory background on alternating tumor treating field (TTFields) therapy, an FDA approved therapy for newly diagnosed glioblastoma, is reviewed in the context of standard temozolomide (TMZ) chemotherapy. The highlighted paper evaluated the potential interactions of TMZ and TTFields in vitro , as this could not be readily accomplished clinically. The authors reported a clinical model using 2 different sets of patient-derived GBM stem-like cells (GSCs) including MGMT-expressing (TMZ resistant) GSC and non-MGMT-expressing (TMZ sensitive) GSC. The results demonstrated no interactions, and the inability of TTFields to overcome TMZ resistance. The significant clinical implications of these results, and the rationale for exploring other innovative treatment strategies in combination with TTFields are discussed.
最近发表的一篇论文的研究亮点:“肿瘤治疗领域(和替莫唑胺)对MGMT表达和非表达的患者源性胶质母细胞瘤细胞的影响”(J clinical Neurosci 2017;(36:120-124)。在标准替莫唑胺(TMZ)化疗的背景下,介绍了FDA批准的用于新诊断的胶质母细胞瘤的交替肿瘤治疗场(TTFields)疗法。这篇突出的论文评估了TMZ和TTFields在体外的潜在相互作用,因为这在临床上很难完成。作者报告了使用2组不同患者来源的GBM干细胞(GSCs)的临床模型,包括表达mgmt - (TMZ耐药)的GSC和不表达mgmt - (TMZ敏感)的GSC。结果表明TTFields没有相互作用,并且无法克服TMZ抗性。本文讨论了这些结果的重要临床意义,以及探索与TTFields结合的其他创新治疗策略的基本原理。
{"title":"Tumor treating field therapy in non-MGMT-Methylated newly diagnosed glioblastoma: is there a role for temozolomide?","authors":"H. Robins, J. Kuo, D. Deming","doi":"10.14800/CCM.1502","DOIUrl":"https://doi.org/10.14800/CCM.1502","url":null,"abstract":"A Research Highlight of a recently published paper: “The effects of tumor treating fields (and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells” (J Clin Neurosci 2017; 36:120-124) is presented. Introductory background on alternating tumor treating field (TTFields) therapy, an FDA approved therapy for newly diagnosed glioblastoma, is reviewed in the context of standard temozolomide (TMZ) chemotherapy. The highlighted paper evaluated the potential interactions of TMZ and TTFields in vitro , as this could not be readily accomplished clinically. The authors reported a clinical model using 2 different sets of patient-derived GBM stem-like cells (GSCs) including MGMT-expressing (TMZ resistant) GSC and non-MGMT-expressing (TMZ sensitive) GSC. The results demonstrated no interactions, and the inability of TTFields to overcome TMZ resistance. The significant clinical implications of these results, and the rationale for exploring other innovative treatment strategies in combination with TTFields are discussed.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88346707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Many are better than one - next generation multivariate biomarkers for precision oncology 许多都比一个更好——精准肿瘤学的下一代多变量生物标志物
Pub Date : 2017-01-09 DOI: 10.14800/CCM.1484
Jinyan Du, D. Kirouac, B. Schoeberl
Existing companion diagnostics have helped to match drug treatments to patients. However, they are largely restricted to single-molecule, single-time-point measurements, which cannot capture the full dynamic complexity of cancer biology. The development of multivariate and even dynamic biomarkers for diagnostic assays could allow more patients to benefit from improved drug regimens. Here we describe our work which provides a case study of multivariate biomarkers where we integrated experimental data generated using multivariate profiling technologies with a variety of computational modeling and simulation methods to identify such biomarkers and make clinical predictions on their therapeutic utility. We believe this approach of integrating multivariate profiling technologies and computational models, and iterating between experimental discovery and model predictions, will be required to develop the next generation of multivariate diagnostics and realize the promise of precision medicine.
现有的伴随诊断有助于将药物治疗与患者相匹配。然而,它们在很大程度上局限于单分子、单时间点测量,无法捕捉到癌症生物学的全部动态复杂性。用于诊断分析的多变量甚至动态生物标志物的发展可以使更多的患者受益于改进的药物治疗方案。在这里,我们描述了我们的工作,提供了一个多变量生物标志物的案例研究,我们将使用多变量分析技术生成的实验数据与各种计算建模和模拟方法相结合,以识别这些生物标志物并对其治疗效用进行临床预测。我们相信,这种整合多元分析技术和计算模型的方法,以及在实验发现和模型预测之间迭代,将是开发下一代多元诊断和实现精准医疗承诺所必需的。
{"title":"Many are better than one - next generation multivariate biomarkers for precision oncology","authors":"Jinyan Du, D. Kirouac, B. Schoeberl","doi":"10.14800/CCM.1484","DOIUrl":"https://doi.org/10.14800/CCM.1484","url":null,"abstract":"Existing companion diagnostics have helped to match drug treatments to patients. However, they are largely restricted to single-molecule, single-time-point measurements, which cannot capture the full dynamic complexity of cancer biology. The development of multivariate and even dynamic biomarkers for diagnostic assays could allow more patients to benefit from improved drug regimens. Here we describe our work which provides a case study of multivariate biomarkers where we integrated experimental data generated using multivariate profiling technologies with a variety of computational modeling and simulation methods to identify such biomarkers and make clinical predictions on their therapeutic utility. We believe this approach of integrating multivariate profiling technologies and computational models, and iterating between experimental discovery and model predictions, will be required to develop the next generation of multivariate diagnostics and realize the promise of precision medicine.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80197877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dendritic cell targeting vaccine for HPV-associated cancer 树突状细胞靶向疫苗用于hpv相关癌症
Pub Date : 2017-01-02 DOI: 10.14800/CCM.1482
Wenjie Yin, D. Duluc, HyeMee Joo, SangKon Oh
Dendritic cells (DCs) are major antigen presenting cells that can efficiently prime and activate cellular immune responses. Delivering antigens to in vivo DCs has thus been considered as a promising strategy that could allow us to mount T cell-mediated therapeutic immunity against cancers in patients. Successful development of such types of cancer vaccines that can target in vivo DCs, however, requires a series of outstanding questions that need to be addressed. These include the proper selection of which DC surface receptors, specific DC subsets and DC activators that can further enhance the efficacy of vaccines by promoting effector T cell infiltration and retention in tumors and their actions against tumors. Supplementing these areas of research with additional strategies that can counteract tumor immune evasion mechanisms is also expected to enhance the efficacy of such therapeutic vaccines against cancers. After more than a decade of study, we have concluded that antigen targeting to DCs via CD40 to evoke cellular responses is more efficient than targeting antigens to the same types of DCs via eleven other DC surface receptors tested. In recent work, we have further demonstrated that a prototype vaccine (anti-CD40-HPV16.E6/7, a recombinant fusion protein of anti-human CD40 and HPV16.E6/7 protein) for HPV16-associated cancers can efficiently activate HPV16.E6/7-specific T cells, particularly CD8+ T cells, from the blood of HPV16+ head-and-neck cancer patients. Moreover, anti-CD40-HPV16.E6/7 plus poly(I:C) can mount potent therapeutic immunity against TC-1 tumor expressing HPV16.E6/7 protein in human CD40 transgenic mice. In this manuscript, we thus highlight our recent findings for the development of novel CD40 targeting immunotherapeutic vaccines for HPV16-associated malignancies. In addition, we further discuss several of key questions that still remain to be addressed for enhancing therapeutic immunity elicited by our prototype vaccine against HPV16-associated malignancies.
树突状细胞是一种主要的抗原呈递细胞,能够有效地启动和激活细胞免疫应答。因此,将抗原递送到体内dc被认为是一种很有前途的策略,可以让我们在患者体内安装T细胞介导的治疗性免疫系统来对抗癌症。然而,成功开发能够靶向体内dc的这类癌症疫苗需要解决一系列悬而未决的问题。这些包括正确选择哪些DC表面受体、特定的DC亚群和DC激活剂,它们可以通过促进效应T细胞在肿瘤中的浸润和滞留以及它们对肿瘤的作用来进一步增强疫苗的效力。用能够抵消肿瘤免疫逃避机制的其他战略补充这些研究领域,也有望提高这种治疗性癌症疫苗的功效。经过十多年的研究,我们已经得出结论,抗原通过CD40靶向DC来激发细胞反应比通过其他11种DC表面受体靶向相同类型的DC更有效。在最近的工作中,我们进一步证明了一种原型疫苗(抗cd40 - hpv16)。E6/7,抗人CD40和HPV16的重组融合蛋白。E6/7蛋白)能有效激活HPV16。来自HPV16+头颈癌患者血液中的e6 /7特异性T细胞,特别是CD8+ T细胞。此外,anti-CD40-HPV16。E6/7 + poly(I:C)可以对表达HPV16的TC-1肿瘤产生有效的治疗性免疫。E6/7蛋白在人CD40转基因小鼠中的表达。因此,在这篇论文中,我们强调了我们最近在开发针对hpv16相关恶性肿瘤的新型CD40靶向免疫治疗疫苗方面的发现。此外,我们进一步讨论了几个关键问题,这些问题仍有待解决,以增强我们针对hpv16相关恶性肿瘤的原型疫苗引起的治疗性免疫。
{"title":"Dendritic cell targeting vaccine for HPV-associated cancer","authors":"Wenjie Yin, D. Duluc, HyeMee Joo, SangKon Oh","doi":"10.14800/CCM.1482","DOIUrl":"https://doi.org/10.14800/CCM.1482","url":null,"abstract":"Dendritic cells (DCs) are major antigen presenting cells that can efficiently prime and activate cellular immune responses. Delivering antigens to in vivo DCs has thus been considered as a promising strategy that could allow us to mount T cell-mediated therapeutic immunity against cancers in patients. Successful development of such types of cancer vaccines that can target in vivo DCs, however, requires a series of outstanding questions that need to be addressed. These include the proper selection of which DC surface receptors, specific DC subsets and DC activators that can further enhance the efficacy of vaccines by promoting effector T cell infiltration and retention in tumors and their actions against tumors. Supplementing these areas of research with additional strategies that can counteract tumor immune evasion mechanisms is also expected to enhance the efficacy of such therapeutic vaccines against cancers. After more than a decade of study, we have concluded that antigen targeting to DCs via CD40 to evoke cellular responses is more efficient than targeting antigens to the same types of DCs via eleven other DC surface receptors tested. In recent work, we have further demonstrated that a prototype vaccine (anti-CD40-HPV16.E6/7, a recombinant fusion protein of anti-human CD40 and HPV16.E6/7 protein) for HPV16-associated cancers can efficiently activate HPV16.E6/7-specific T cells, particularly CD8+ T cells, from the blood of HPV16+ head-and-neck cancer patients. Moreover, anti-CD40-HPV16.E6/7 plus poly(I:C) can mount potent therapeutic immunity against TC-1 tumor expressing HPV16.E6/7 protein in human CD40 transgenic mice. In this manuscript, we thus highlight our recent findings for the development of novel CD40 targeting immunotherapeutic vaccines for HPV16-associated malignancies. In addition, we further discuss several of key questions that still remain to be addressed for enhancing therapeutic immunity elicited by our prototype vaccine against HPV16-associated malignancies.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87487707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Brain derived neutrophic factor (BDNF) coordinates lympho-vascular metastasis through a fibroblast-governed paracrine axis in the tumor microenvironment. 脑源性中性营养因子(BDNF)在肿瘤微环境中通过成纤维细胞调控的旁分泌轴协调淋巴血管转移。
Pub Date : 2017-01-01 Epub Date: 2017-07-10 DOI: 10.14800/ccm.1566
Tilahun Jiffar, Turker Yilmaz, Junegoo Lee, Yair Miller, Lei Feng, Adel El-Naggar, Michael E Kupferman

It has long been known that the tumor microenvironment contributes to the proliferation and survival of neoplasms through the constant interaction with the stromal and immune compartments. In this investigation, we explored the role of cancer-associated fibroblasts (CAFs) in the regulation of the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC) though a complex intercellular BDNF-TrkB signaling system. Our studies show that conditioned media derived from patient-derived CAFs promoted HNSCC cell proliferation, in vitro cell migration, cell invasion and chemotherapy resistance, compared to normal fibroblasts. Furthermore, examination of the in vivo impact of CAF pathophysiology in the tumor microenvironment in animal xenograft models revealed that HNSCC cell lines in combination with CAFs promoted tumor growth and increased incidence of lymphovascular metastasis as compared to injection of tumor cells or CAF cells alone. Using pharmacological and genetic alterations, we mechanistically demonstrate the critical importance of BDNF-TrkB signaling in the tumor microenvironment. These investigations further support the rationale for BDNF/TRKB targeted therapy against in the treatment of HNSCC.

人们早就知道,肿瘤微环境通过与间质和免疫室的持续相互作用,促进肿瘤的增殖和存活。在这项研究中,我们探讨了癌症相关成纤维细胞(CAFs)通过复杂的细胞间BDNF-TrkB信号系统在头颈部鳞状细胞癌(HNSCC)中调节肿瘤微环境的作用。我们的研究表明,与正常成纤维细胞相比,来自患者源性CAFs的条件培养基促进了HNSCC细胞的增殖、体外细胞迁移、细胞侵袭和化疗耐药性。此外,在动物异种移植模型中对肿瘤微环境中CAF病理生理的体内影响的研究显示,与单独注射肿瘤细胞或CAF细胞相比,与CAF联合使用的HNSCC细胞系促进了肿瘤的生长,增加了淋巴血管转移的发生率。通过药理和遗传改变,我们从机制上证明了BDNF-TrkB信号在肿瘤微环境中的重要作用。这些研究进一步支持了BDNF/TRKB靶向治疗HNSCC的基本原理。
{"title":"Brain derived neutrophic factor (BDNF) coordinates lympho-vascular metastasis through a fibroblast-governed paracrine axis in the tumor microenvironment.","authors":"Tilahun Jiffar,&nbsp;Turker Yilmaz,&nbsp;Junegoo Lee,&nbsp;Yair Miller,&nbsp;Lei Feng,&nbsp;Adel El-Naggar,&nbsp;Michael E Kupferman","doi":"10.14800/ccm.1566","DOIUrl":"https://doi.org/10.14800/ccm.1566","url":null,"abstract":"<p><p>It has long been known that the tumor microenvironment contributes to the proliferation and survival of neoplasms through the constant interaction with the stromal and immune compartments. In this investigation, we explored the role of cancer-associated fibroblasts (CAFs) in the regulation of the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC) though a complex intercellular BDNF-TrkB signaling system. Our studies show that conditioned media derived from patient-derived CAFs promoted HNSCC cell proliferation, in vitro cell migration, cell invasion and chemotherapy resistance, compared to normal fibroblasts. Furthermore, examination of the <i>in vivo</i> impact of CAF pathophysiology in the tumor microenvironment in animal xenograft models revealed that HNSCC cell lines in combination with CAFs promoted tumor growth and increased incidence of lymphovascular metastasis as compared to injection of tumor cells or CAF cells alone. Using pharmacological and genetic alterations, we mechanistically demonstrate the critical importance of BDNF-TrkB signaling in the tumor microenvironment. These investigations further support the rationale for BDNF/TRKB targeted therapy against in the treatment of HNSCC.</p>","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14800/ccm.1566","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35459535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Protein synthesis inhibition enhances paraptotic death induced by inhibition of cyclophilins in glioblastoma cells. 蛋白合成抑制增强胶质母细胞瘤细胞亲环蛋白抑制诱导的旁细胞性死亡。
Pub Date : 2017-01-01 Epub Date: 2017-10-02
Lin Wang, Justin H Gundelach, Richard J Bram

Treatment of cancer is frequently unsuccessful related to the loss of apoptotic signaling in malignant cells. This is a particular problem for high-grade gliomas, such as Glioblastoma Multiforme (GBM), which are almost universally fatal within a year or so of diagnosis. Novel therapies that capitalize on non-apoptotic cell death pathways may yield more effective outcomes, if their underlying mechanisms can be more completely deciphered. In a recent publication (ref 10), the mechanisms by which cellular cyclophilins support GBM cell survival have been identified. Inhibition of cyclophilins activated paraptosis, which relied on a combination of endoplasmic reticulum (ER) stress and transient activation of autophagy. An important aspect of this effect was the relative rates of cap-dependent versus cap-independent protein synthesis, which were differentially modulated by protein synthesis inhibitors or mTOR inhibition. Although cycloheximide has previously been characterized as an inhibitor of paraptosis, in the case of cyclophilin inhibition, it appears to significantly enhance stress-related paraptosis and cell death. This work reveals an important role for cap-independent protein translation and autophagy in the ability of GBM cells to resist non-apoptotic death, and adds to our understanding of the events that underlie paraptosis.

癌症的治疗常常不成功,这与恶性细胞中凋亡信号的丢失有关。对于高级别胶质瘤,如多形性胶质母细胞瘤(GBM),这是一个特殊的问题,几乎普遍在诊断后一年左右死亡。利用非凋亡细胞死亡途径的新疗法可能产生更有效的结果,如果它们的潜在机制可以更彻底地破译。在最近的一篇文章中(参考文献10),细胞亲环蛋白支持GBM细胞存活的机制已经被确定。抑制亲环蛋白激活细胞旁噬,这依赖于内质网(ER)应激和自噬的短暂激活的组合。这种影响的一个重要方面是帽依赖与帽独立蛋白质合成的相对比率,这是由蛋白质合成抑制剂或mTOR抑制的差异调节。虽然环己亚胺以前被认为是一种细胞凋亡抑制剂,但在亲环蛋白抑制的情况下,它似乎显著增强了与应激相关的细胞凋亡和细胞死亡。这项工作揭示了帽独立蛋白翻译和自噬在GBM细胞抵抗非凋亡性死亡的能力中的重要作用,并增加了我们对细胞凋亡背后事件的理解。
{"title":"Protein synthesis inhibition enhances paraptotic death induced by inhibition of cyclophilins in glioblastoma cells.","authors":"Lin Wang,&nbsp;Justin H Gundelach,&nbsp;Richard J Bram","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Treatment of cancer is frequently unsuccessful related to the loss of apoptotic signaling in malignant cells. This is a particular problem for high-grade gliomas, such as Glioblastoma Multiforme (GBM), which are almost universally fatal within a year or so of diagnosis. Novel therapies that capitalize on non-apoptotic cell death pathways may yield more effective outcomes, if their underlying mechanisms can be more completely deciphered. In a recent publication (ref 10), the mechanisms by which cellular cyclophilins support GBM cell survival have been identified. Inhibition of cyclophilins activated paraptosis, which relied on a combination of endoplasmic reticulum (ER) stress and transient activation of autophagy. An important aspect of this effect was the relative rates of cap-dependent versus cap-independent protein synthesis, which were differentially modulated by protein synthesis inhibitors or mTOR inhibition. Although cycloheximide has previously been characterized as an inhibitor of paraptosis, in the case of cyclophilin inhibition, it appears to significantly enhance stress-related paraptosis and cell death. This work reveals an important role for cap-independent protein translation and autophagy in the ability of GBM cells to resist non-apoptotic death, and adds to our understanding of the events that underlie paraptosis.</p>","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35560067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The regulation of snail: on the ubiquitin edge. 蜗牛的调控:在泛素边缘上。
Pub Date : 2017-01-01 Epub Date: 2017-07-03
Qian Yu, Binhua P Zhou, Yadi Wu

Metastasis accounts for a majority of cancer death. One key feature during metastasis is epithelial-mesenchymal transition (EMT), which is regulated by transcription factors such as Snail and Twist. In non-malignant cells, Snail has a short half-life and is degraded via ubiquitination, but its stability is increased in cancer cell. However, the mechanism by which Snail escapes ubiquitination and degradation remains unknown. Recently, we found that Dub3 is a deubiquinase of Snail. Most importantly, we determined that Dub3 responded to extracellular signals such as IL-6, and that the resultant signaling prevented Snail degradation, and promoted cancer growth, invasion, and migration. In this highlight, we present a concise picture of how the transcription factor Snail is regulated by ubiquitination in cancer cells, the role of Dub3 in this process, and its potential use as a treatment target.

转移是癌症死亡的主要原因。转移过程中的一个关键特征是上皮-间质转化(EMT),这是由转录因子如Snail和Twist调节的。在非恶性细胞中,蜗牛的半衰期短,可通过泛素化降解,但在癌细胞中其稳定性增加。然而,蜗牛逃脱泛素化和降解的机制尚不清楚。最近,我们发现Dub3是蜗牛的一种去泛素酶。最重要的是,我们确定Dub3对细胞外信号如IL-6有反应,由此产生的信号阻止了Snail降解,并促进了癌症的生长、侵袭和迁移。在这篇重点文章中,我们简要介绍了癌细胞中转录因子Snail是如何被泛素化调节的,Dub3在这一过程中的作用,以及它作为治疗靶点的潜在用途。
{"title":"The regulation of snail: on the ubiquitin edge.","authors":"Qian Yu,&nbsp;Binhua P Zhou,&nbsp;Yadi Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Metastasis accounts for a majority of cancer death. One key feature during metastasis is epithelial-mesenchymal transition (EMT), which is regulated by transcription factors such as Snail and Twist. In non-malignant cells, Snail has a short half-life and is degraded via ubiquitination, but its stability is increased in cancer cell. However, the mechanism by which Snail escapes ubiquitination and degradation remains unknown. Recently, we found that Dub3 is a deubiquinase of Snail. Most importantly, we determined that Dub3 responded to extracellular signals such as IL-6, and that the resultant signaling prevented Snail degradation, and promoted cancer growth, invasion, and migration. In this highlight, we present a concise picture of how the transcription factor Snail is regulated by ubiquitination in cancer cells, the role of Dub3 in this process, and its potential use as a treatment target.</p>","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35561196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer cell & microenvironment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1